Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 8/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | DOHH | Q9BU89 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | GAA | P10253 | 1/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.92 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17109729 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL21051754 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL10498260 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL34571 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL19040665 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL26511991 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| SCHEMBL17100575 | 1.00 | KDM4A (1.00) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL20658962 | 0.99 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL21049242 | 0.99 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E | |
| Deferoxamine SCHEMBL20658960 | 0.99 | KDM4A (0.97) | KDM4AHIF1ATET2DOHHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20230270894-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | REGENERON PHARMACEUTICALS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | Bicyclerd Limited (GB) | 2021-03-18 | — | — | US | disclosed |
| US-8487079-B2 | Use of mitochondria-targeted electron scavengers as anti-inflammatory agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487079-B2 | Use of mitochondria-targeted electron scavengers as anti-inflammatory agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100111856-A1 | ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | HAGH, COX5B, HSPE1 | KDM4A 4555/4885HIF1A 648/4885TET2 1850/4885 |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | KDM4A 4814/4885HIF1A 3207/4885TET2 4809/4885 |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | VIP, NGLY1, GRPR | KDM4A 4814/4885HIF1A 3207/4885TET2 4809/4885 |
| US-20230270894-A1 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | LGALS3, LGALS3BP, CD47 | KDM4A 2186/4885HIF1A 1338/4885TET2 4442/4885 |
| US-20100111856-A1 | ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES | ZYX, LNPEP, ZKSCAN2 | KDM4A 3551/4885HIF1A 4127/4885TET2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.